Subclinical cardiovascular damage in patients with HCV cirrhosis before and after treatment with direct antiviral agents: a prospective study

Summary Background Cirrhosis is associated with morpho‐functional cardiovascular alterations. Aims To detect early features of cardiovascular damage in HCV ‐compensated cirrhotic patients using myocardial deformation indices and carotid arterial stiffness, and, further, to evaluate their short‐term behaviour after HCV eradication with direct antiviral agents ( DAA s). Methods Thirty‐nine consecutive patients with HCV cirrhosis, without previous cardiovascular events, were studied and matched for age, gender and cardiovascular risk factors to 39 controls without liver or cardiovascular disease. Patients and controls underwent a baseline echocardiographic evaluation including global longitudinal strain and ultrasound scan of carotid arteries. HCV ‐cirrhotics were reassessed by echocardiography and carotid ultrasound after obtaining sustained virological response ( SVR ) on DAA s. Results HCV ‐cirrhotics showed at baseline a significantly reduced global longitudinal strain compared to controls −18.1 (16.3‐20.5) vs −21.2 (20.4‐22.3), P < 0.001 . They also had a significantly higher pulse wave velocity 8.6 (7.7‐9.1) m/s vs 6.6 (6.0‐7.1) m/s, P = 0.0001, and β‐stiffness index 12.4 (11.1‐13.5) vs 8.6 (8.0‐9.2) P = 0.0001. At multiple regression analysis, diabetes and HCV cirrhosis were independent predictors of global longitudinal strain. All HCV ‐cirrhotic patients had SVR on DAA s. Follow‐up available in 32 of 39 (82%) at 9 (8‐10) months showed a significant improvement of tricuspid annular plane systolic excursion ( P = 0.01 ) and lateral E’ velocity compared to baseline ( P = 0.001). Conclusions HCV ‐cirrhotics show a significant rate of subclinical cardiac and vascular abnormalities. At a time when their survival is less linked to progression of liver disease, due to viral eradication on DAA s, cardiovascular morbidity and mortality may take a significant role.